CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 32 enrolled
Drug / intervention
LIB003drug
Likely dose
LIB003 300 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT03847974
NCT03847974Phase 2Completed
CompareCT.gov

Open-Label Extension, Phase 2b Study to Evaluate the Longer Term Efficacy and Safety of LIB003 in Patients on Stable Lipid Lowering Therapy Requiring Additional LDL-C Reduction

LIB Therapeutics LLC·interventional·Posted Feb 20, 2019·Updated Mar 2, 2022

In Brief

A Phase 2 clinical trial evaluating LIB003 for Hypercholesterolemia. Completed, enrolled 32 participants across 3 sites.

Detailed Summary

To assess the longer term safety, tolerability, and LDL C lowering efficacy after 52 weeks of additional treatment with LIB003 with subcutaneous (SC) dosing every 4 weeks (Q4W)

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHypercholesterolemia
CountriesUnited States
Collaborators--

Timeline

Phase 2CompletedFinished
20192020202120222023202420252026
First PostedFeb 20, 2019
Enrollment StartFeb 14, 2019
Primary CompletionApr 7, 2020
Study CompletionAug 31, 2020
TodayJul 2, 2026
Enrollment to primary: 1.1 yearsPosted 7.4 years ago

Interventions

LIB003drug

300 mg SC Q4W